Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EDIT Editas Medicine

Post-Mkt 02-27 19:55:12 EST

2.20

+0.02

+0.92%

盘后2.19

-0.01-0.42%

19:33 EST

High2.29	Low2.11	Vol1.95M
Open2.11	D1 Closing2.18	Amplitude8.03%
Mkt Cap214.76M	Tradable Cap197.08M	Total Shares97.62M
T/O4.30M	T/O Rate2.17%	Tradable Shares89.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EDIT","market":"US","secType":"STK","nameCN":"Editas Medicine","latestPrice":2.2,"timestamp":1772226000000,"preClose":2.18,"halted":0,"volume":1946783,"hourTrading":{"tag":"盘后","latestPrice":2.1907,"preClose":2.2,"latestTime":"19:33 EST","volume":21717,"amount":47232.3293604,"timestamp":1772238788997,"change":-0.0093,"changeRate":-0.004227,"amplitude":0.036364},"delay":0,"changeRate":0.009174311926605512,"floatShares":89583600,"shares":97618660,"eps":-2.349266,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"02-27 19:55:12 EST","open":2.11,"high":2.285,"low":2.11,"amount":4304966.9973005,"amplitude":0.080275,"askPrice":2.2,"askSize":226,"bidPrice":2.14,"bidSize":50,"shortable":3,"etf":0,"ttmEps":-2.349266,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1772240400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.18,"preHourTrading":{"tag":"盘前","latestPrice":2.12,"preClose":2.18,"latestTime":"09:29 EST","volume":890,"amount":1870.163408,"timestamp":1772202560218,"change":-0.06,"changeRate":-0.027523,"amplitude":0.042936},"postHourTrading":{"tag":"盘后","latestPrice":2.1907,"preClose":2.2,"latestTime":"19:33 EST","volume":21717,"amount":47232.3293604,"timestamp":1772238788997,"change":-0.0093,"changeRate":-0.004227,"amplitude":0.036364},"volumeRatio":0.941835,"impliedVol":0.6251,"impliedVolPercentile":0.1474},"requestUrl":"/m/hq/s/EDIT","defaultTab":"news","newsList":[{"id":"2614859196","title":"Editas Medicine Inc  expected to post a loss of 26 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2614859196","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614859196?lang=en_us&edition=fundamental","pubTime":"2026-02-27 21:41","pubTimestamp":1772199665,"startTime":"0","endTime":"0","summary":"Editas Medicine Inc  expected to post a loss of26cents a share - Earnings Preview Editas Medicine Inc EDIT.OQ EDIT.O is expected to  show a fall in quarterly revenue when it reports  results on March ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL8N3ZN1JW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDIT","BK4556"],"gpt_icon":0},{"id":"2613787035","title":"Editas Medicine to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613787035","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613787035?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:00","pubTimestamp":1771855200,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242678/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EDIT","BK4556"],"gpt_icon":0},{"id":"2612740965","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2612740965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612740965?lang=en_us&edition=fundamental","pubTime":"2026-02-19 19:00","pubTimestamp":1771498800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Cushman & Wake.                                   4Q       .54    7:00 AM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FIX","ALRM","FND","EXR","BBDC","EIG","CENX","CWK","AGM","AMH","BABA","CWST","COLD","ASIC","BALY","AGM.A","DTM","CEG","CCCC","APPN","EDIT","ACH","BAND","CTO","ALIT","CNP","CQP","CVE","DE","EWTX","DBX","ARDX","CC","CHH","CPRT","CGAU","DAVA","EPAM","AKAM","ED","AG","FIVN","ETSY","FOLD","CARG","EGO","AMN","AXTI","FNF","EVRG"],"gpt_icon":1},{"id":"2612429049","title":"Press Release: ONE Gas Announces Fourth Quarter and Full Year 2025 Financial Results; Releases Non-GAAP Adjusted Financial Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2612429049","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612429049?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:20","pubTimestamp":1771449600,"startTime":"0","endTime":"0","summary":"Analyst call and webcast scheduled tomorrow, Feb. 19 at 11 a.m. EST. TULSA, Okla., Feb. 18, 2026 /PRNewswire/ -- ONE Gas, Inc.  today announced its fourth quarter and full year 2025 financial results, which include diluted earnings per share of $1.42 and $4.37, respectively. The Company also provided non--GAAP adjustments to both earnings and its 2026 financial guidance to capture the full impact of a regulatory mechanism intended to mitigate regulatory lag. Adjusted net income was $1.48 per diluted share for the fourth quarter, and $4.48 per diluted share for the full year 2025. For 2026, non--GAAP earnings are expected to range from $306 million to $314 million, or $4.83 to $4.95 per diluted share.\"Our team delivered strong operational and financial results in 2025, reflecting disciplined execution and a commitment to safely serving our communities,\" said Robert S. McAnnally, president and chief executive officer. \"Looking ahead, we see meaningful opportunity in both residential and ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","LU0566484027.USD","BK4139","BK4556","LU1559883803.SGD","OGS","BK4197"],"gpt_icon":0},{"id":"2603067974","title":"Edita Food Enters Into A Sale And Assignment Agreement With Hostess Brands","url":"https://stock-news.laohu8.com/highlight/detail?id=2603067974","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603067974?lang=en_us&edition=fundamental","pubTime":"2026-01-15 15:17","pubTimestamp":1768461471,"startTime":"0","endTime":"0","summary":"Jan 15 (Reuters) - EDITA FOOD INDUSTRIES ::*ENTERED INTO A SALE AND ASSIGNMENT AGREEMENT WITH HOSTESS BRANDS*ACQUIRES TRADEMARKS, BRAND NAMES, AND GOODWILL RELATING TO HOHOS, TWINKIES, TIGER TAIL BRAN","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nRSD6z8PNm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4588","EDIT","BK4585","BK4139","SJM","BK4212"],"gpt_icon":0},{"id":"2583674560","title":"Chardan Capital Upgrades Editas Medicine to Buy From Neutral, Price Target is $3.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2583674560","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583674560?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:54","pubTimestamp":1763038448,"startTime":"0","endTime":"0","summary":"Editas Medicine (EDIT) has an average rating of overweight and mean price target of $4.91, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EDIT"],"gpt_icon":0},{"id":"2583581835","title":"Editas Medicine price target lowered to $3.50 from $12 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2583581835","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583581835?lang=en_us&edition=fundamental","pubTime":"2025-11-13 06:30","pubTimestamp":1762986652,"startTime":"0","endTime":"0","summary":"Chardan lowered the firm’s price target on Editas Medicine (EDIT) to $3.50 from $12 and keeps a Buy rating on the shares. The firm updated its Edit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/editas-medicine-price-target-lowered-to-3-50-from-12-at-chardan-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/editas-medicine-price-target-lowered-to-3-50-from-12-at-chardan-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT"],"gpt_icon":0},{"id":"2582892390","title":"Cautious Hold Rating on Editas Medicine Amid Promising Preclinical Results and Development Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2582892390","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582892390?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:16","pubTimestamp":1762895818,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy has maintained their neutral stance on EDIT stock, giving a Hold rating today. Soumit Roy has given his Hold rating...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-hold-rating-on-editas-medicine-amid-promising-preclinical-results-and-development-uncertainties-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-hold-rating-on-editas-medicine-amid-promising-preclinical-results-and-development-uncertainties-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT"],"gpt_icon":0},{"id":"2582362335","title":"Analysts Offer Insights on Healthcare Companies: Editas Medicine (EDIT) and Guardian Pharmacy Services, Inc. Class A (GRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582362335","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582362335?lang=en_us&edition=fundamental","pubTime":"2025-11-11 21:50","pubTimestamp":1762869018,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Editas Medicine (EDIT – Research Report) and Guard...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-editas-medicine-edit-and-guardian-pharmacy-services-inc-class-a-grdn-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-editas-medicine-edit-and-guardian-pharmacy-services-inc-class-a-grdn-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4556","XBI","BK4588","LU0128526141.USD","LU0029874061.USD","BK4196","BK4139","BK4128","BK4137","BK4581","EDIT","LABU","HCSG","BK4585","GRDN"],"gpt_icon":0},{"id":"2582351368","title":"Barclays Keeps Their Hold Rating on Editas Medicine (EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582351368","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582351368?lang=en_us&edition=fundamental","pubTime":"2025-11-11 16:56","pubTimestamp":1762851376,"startTime":"0","endTime":"0","summary":"Barclays analyst Gena Wang maintained a Hold rating on Editas Medicine today and set a price target of $3.00. Wang covers the Healthcare sector, fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-editas-medicine-edit-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-keeps-their-hold-rating-on-editas-medicine-edit-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EDIT"],"gpt_icon":0},{"id":"2582339992","title":"Editas Medicine Reports Q3 2025 Progress and Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2582339992","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582339992?lang=en_us&edition=fundamental","pubTime":"2025-11-11 12:10","pubTimestamp":1762834226,"startTime":"0","endTime":"0","summary":"Editas Medicine Inc. ( ($EDIT) ) has released its Q3 earnings. Here is a breakdown of the information Editas Medicine Inc. presented to its investo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/editas-medicine-reports-q3-2025-progress-and-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/editas-medicine-reports-q3-2025-progress-and-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","BK4097","BK4556","LU2065732104.USD","BK4139","EDIT"],"gpt_icon":0},{"id":"2582875190","title":"Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875190","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875190?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:21","pubTimestamp":1762777288,"startTime":"0","endTime":"0","summary":"Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 5.08 percent. This is a 62.67 percent increase over losses of $(0.75) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48748496/editas-medicine-q3-eps-0-28-beats-0-29-estimate-sales-7-543m-beat-5-020m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT"],"gpt_icon":0},{"id":"2582873084","title":"Editas Medicine Q3 net loss narrows, beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873084","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873084?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:08","pubTimestamp":1762776515,"startTime":"0","endTime":"0","summary":"Editas Medicine Q3 net loss narrows, beats expectationsOverviewEditas Q3 net loss decreases to $25.1 mln, beating analyst expectationsCollaboration revenue rises to $7.5 mln, driven by BMS milestone a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0D7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","EDIT"],"gpt_icon":0},{"id":"2582873789","title":"Editas Medicine Reports Q3 2025 Results and Advances EDIT-401 Toward Human Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873789","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873789?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:05","pubTimestamp":1762776332,"startTime":"0","endTime":"0","summary":"Editas Medicine Inc. reported its third quarter 2025 financial results and provided business updates. The company highlighted preclinical proof-of-concept data presented at the American Heart Association  and the European Society of Gene and Cell Therapy , demonstrating that its lead candidate, EDIT-401, achieved over 90% reduction in LDL cholesterol levels in non-human primates. In mouse models, the LDL-C reduction was maintained over a three-month study, supporting the durability of the effect. Editas Medicine remains on track to submit an investigational new drug  or clinical trial application  for EDIT-401 by mid-2026, with initial human proof-of-concept data anticipated by year-end 2026. The company has extended its cash runway into the third quarter of 2027 through proceeds from sales of its common stock under its at-the-market facility and continued financial discipline. Editas also announced participation in the 8th Annual Evercore Healthcare Conference on December 2, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL49YDmy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","EDIT","BK4556","EVR","BK4139"],"gpt_icon":0},{"id":"2582873668","title":"BRIEF-Editas Medicine Q3 Net Income USD -25.117 Million Vs. IBES Estimate USD -28.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873668","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873668?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776047,"startTime":"0","endTime":"0","summary":"Nov 10  - Editas Medicine Q3 operating expenses USD 32.091 million.Q3 collaboration and other research and development revenue USD 7.5 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX86D8AC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4139","BK4556"],"gpt_icon":0},{"id":"2582873359","title":"Editas Medicine Announces Third Quarter 2025 Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873359","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873359?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776004,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUADXJK3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EDIT","BK4139","BK4556"],"gpt_icon":0},{"id":"2582875342","title":"Editas Medicine Inc: on Track to Submit Ind/Cta for Edit-401 by Mid-2026, Achieve Initial Human Proof-of-Concept Data by Year-End 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2582875342","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582875342?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX86D8AC:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","EDIT"],"gpt_icon":0},{"id":"2582873333","title":"Editas Medicine Q3 Operating Income USD -24.548 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873333","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873333?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX86D8AC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EDIT","BK4556"],"gpt_icon":0},{"id":"2582187388","title":"Editas Medicine Q3 Net Income USD -25.117 Million VS. Ibes Estimate USD -28.1 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582187388","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582187388?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLX86D8AC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4556","EDIT","BK4139"],"gpt_icon":0},{"id":"2580223551","title":"Press Release: ONE Gas Announces Third Quarter 2025 Financial Results; Narrows 2025 Financial Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2580223551","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580223551?lang=en_us&edition=fundamental","pubTime":"2025-11-04 05:15","pubTimestamp":1762204500,"startTime":"0","endTime":"0","summary":"Analyst call and webcast scheduled tomorrow, November 4 at 11 a.m. EST. TULSA, Okla., Nov. 3, 2025 /PRNewswire/ -- ONE Gas, Inc.  today announced its third quarter financial results, narrowed its 2025 financial guidance and declared its quarterly dividend.\"Our third-quarter performance reflects disciplined execution of our strategy and continued operational efficiency,\" said Robert S. McAnnally, president and chief executive officer. \"The narrowed financial outlook aligns with year-to-date results and reinforces our confidence in delivering full-year guidance. As we approach year-end, we remain focused on sustainable growth, prudent capital deployment and delivering long-term value for our shareholders.\". -- Third quarter 2025 net income was $26.5 million, or $0.44 per diluted. share, compared with $19.3 million, or $0.34 per diluted share, in the. -- The Company narrowed its 2025 diluted earnings per share guidance to a. range of $4.34 to $4.40, from a previous range of $4.32 to $4.42","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4197","RRC","BK4139","BK4213","BK4585","BK4588","BK4556","LU1559883803.SGD","EDIT","LU0566484027.USD","OGS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.editasmedicine.com","stockEarnings":[{"period":"1week","weight":0.2044},{"period":"1month","weight":0.0332},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1518},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.0634}],"compareEarnings":[{"period":"1week","weight":0.007},{"period":"1month","weight":-0.0089},{"period":"3month","weight":0.0086},{"period":"6month","weight":0.0686},{"period":"1year","weight":0.1594},{"period":"ytd","weight":0.0108}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.048743},{"month":2,"riseRate":0.5,"avgChangeRate":0.074352},{"month":3,"riseRate":0.3,"avgChangeRate":-0.071533},{"month":4,"riseRate":0.4,"avgChangeRate":-0.024583},{"month":5,"riseRate":0.5,"avgChangeRate":0.001154},{"month":6,"riseRate":0.6,"avgChangeRate":0.089853},{"month":7,"riseRate":0.7,"avgChangeRate":0.035578},{"month":8,"riseRate":0.6,"avgChangeRate":0.036188},{"month":9,"riseRate":0.2,"avgChangeRate":-0.076361},{"month":10,"riseRate":0.4,"avgChangeRate":-0.058936},{"month":11,"riseRate":0.5,"avgChangeRate":0.071042},{"month":12,"riseRate":0.3,"avgChangeRate":0.023099}],"exchange":"NASDAQ","name":"Editas Medicine","nameEN":"Editas Medicine"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Editas Medicine(EDIT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Editas Medicine,EDIT,Editas Medicine股票,Editas Medicine股票老虎,Editas Medicine股票老虎国际,Editas Medicine行情,Editas Medicine股票行情,Editas Medicine股价,Editas Medicine股市,Editas Medicine股票价格,Editas Medicine股票交易,Editas Medicine股票购买,Editas Medicine股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Editas Medicine(EDIT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Editas Medicine(EDIT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction